C4X Discovery Holdings plc (AIM: C4XD) said it had presented pre-clinical data at a leading industry conference that strengthens the evidence base backing the potential of its anti-addiction drug.
Orexin-1 is being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.
On Saturday (Nov 11) at the Neuroscience 2017 meeting, in Washington DC, delegates were furnished with new efficacy stats generated by the company’s lead compound, C4X_3256.
The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.
C4X said the latest information supported the development of C4X_3256 as a therapy across two distinct areas of nicotine abuse: smoking cessation and relapse in smokers.
READ: C4X Discovery Holdings says it is on course to become a self-sustaining drugs discovery 'engine'
"This set of studies strengthens C4XD's pre-clinical data package for our lead Orexin-1 antagonist programme,” added the firm’s chief executive, Clive Dix.
“We strongly believe that the programme presents a compelling commercial case for partnership due to its broad applicability to substance use as well as related disorders, such as anxiety, post-traumatic stress disorder, and impulse control.
“This is supported by the high level of pre-clinical partnering interest received that have enabled us to enter late-stage commercial discussions."